Cell therapy for Heart Failure Texas Heart Institute

From the Texas Heart Institute: “Investigators in this landmark clinical trial have shown that a special immunomodulatory cell type called MPC (mesenchymal precursor cells) developed by Mesoblast Inc. has the potential for the first time to address a major contributor to heart failure—inflammation. Patients in the trial were on full guideline-recommended drug therapy for heart failure, suggesting that the effect of the cell therapy was synergistic with and additive to state-of-the-art heart failure medications.”       MORE

Image Credit:   Texas Heart Institute